Semaglutide: evidenza tat-titoli u limiti

Punti ewlenin

X'inhu: Agonist tar-riċettur GLP-1. Injezzjoni kull ġimgħa; forma orali ta' kuljum teżisti wkoll.
Licenzjat għal: Diabete tat-tip 2 u, fid-dosijiet ogħla, ġestjoni tal-piż
X'juru t-titoli: STEP 1 rapporta madwar 15% tnaqqis medju fil-piż tal-ġisem fi 68 ġimgħat kontra madwar 2.4% fuq placebo. SELECT rapporta aktar tard tnaqqis fl-avvenimenti kardjovaskulari avversi kbar f'persuni b'piż żejjed u mard kardjovaskulari stabbilit iżda mingħajr diabete.
Il-problema: Effetti gastrointestinali huma komuni u huma r-raġuni normali għalfejn in-nies jieqfu. Ir-reġistrazzjoni tal-piż wara l-waqfien hija sostanzjali u dokumentata sew — STEP 4 wera li l-maġġoranza tat-telf terġa' lura fi żmien sena mingħajr trattament.
Ir-reġistrazzjoni tal-piż wara li tieqaf hija r-regola, mhux l-eċċezzjoni. Dawn huma trattamenti għal kundizzjoni kronika, mhux kors li tlesti.

ეს არ არის სამედიცინო რჩევა

ჰენდა გრაინი გაწვდავს ინფორმაციას, რომელიც გამოქვეყნებულია კლინიკურ კვლევებში. ეს არ არის რჩევა შენთვის, ეს არ არის ინფორმაცია დოზირების შესახებ, როგორც რეკომენდირებული მომხმარებლისთვის და შენ არ იცი შენი კლინიკური მიმდინარეობა. არსებობს რეალური გასტროენტეროლოგიური და პანკრეატული რისკები, რომლებიც დაკავშირებულია ინკრეტინებთან, და ეს რისკები გამოიყენება, როდესაც ისინი დადასტურებულია და რეკომენდირებულია.

X'jappoġġja l-evidenza

Effetti gastrointestinali huma komuni u huma r-raġuni normali għalfejn in-nies jieqfu. Ir-reġistrazzjoni tal-piż wara l-waqfien hija sostanzjali u dokumentata sew — STEP 4 wera li l-maġġoranza tat-telf terġa' lura fi żmien sena mingħajr trattament.

Semaglutide huwa klassifikat bħala stabbilit. Il-grad jiddeskrivi l-kwalità tal-evidenza tat-titoli, mhux kemm se jkun adattat il-mediċina għal kwalunkwe individwu — u l-unika entrata klassifikata bħala "popolari iżda dgħajfa" hija hemm eżattament minħabba li hija mibjugħa ħafna u qatt ma ġiet ittestjata. Gradi assenjati mill-programm tat-titoli u l-istatus regolatorju.

X'jiġri meta tieqaf

Dan huwa l-parti mill-istampa li ħafna drabi titħalla barra. It-titoli ta' rtirar juru b'mod konsistenti reġistrazzjoni sostanzjali tal-piż fi żmien sena wara li tieqaf, u l-markaturi kardjometaboli jerġgħu lura magħha ^[2]. Dan mhux falliment tal-mediċina — huwa kif tidher it-trattament ta' kundizzjoni kronika bi mediċina meta l-mediċina tiġi meħlusa.

L-implikazzjoni prattika hija li d-deċiżjoni li tibda hija deċiżjoni dwar orizzont twil, inkluż il-kost u l-aċċess matul dak l-orizzont, minflok dwar piż target.

Massa tal-muskoli

Telf rapidu tal-piż minn kwalunkwe kawża jinkludi tessut leani, u t-titoli inkretini mhumiex eċċezzjoni. Il-proporzjon mitluf bħala massa leani jidher ġeneralment simili għal metodi oħra ta' telf rapidu, iżda t-telf assolut huwa akbar minħabba li t-telf totali huwa akbar. Proteina adegwata u taħriġ ta' reżistenza huma l-interventi li għandhom evidenza warajhom, u t-tnejn huma fil-kontroll tiegħek waqt li qed tieħu l-mediċina.

Mediċini oħra f'din il-kategorija

Tirzepatide — Agonist duali GIP / GLP-1, stabbilit
Liraglutide — Agonist tar-riċettur GLP-1, stabbilit
Dulaglutide — Agonist tar-riċettur GLP-1, stabbilit
Oral semaglutide — Agonist tar-riċettur GLP-1, orali, promettenti
Preparazzjonijiet GLP-1 komposti — Preparazzjoni komposta mhux approvata, popolari iżda dgħajfa

Kemm piż jitilfu n-nies fuq semaglutide?

STEP 1 rapporta madwar 15% tnaqqis medju fil-piż tal-ġisem fi 68 ġimgħat kontra madwar 2.4% fuq placebo. SELECT rapporta aktar tard tnaqqis fl-avvenimenti kardjovaskulari avversi kbar f'persuni b'piż żejjed u mard kardjovaskulari stabbilit iżda mingħajr diabete. Dawn huma l-mezzi tat-titoli; ir-risposta individwali varja ħafna u l-parteċipanti tat-titoli jirċievu appoġġ li huwa parti mill-riżultat.

X'jiġri jekk nieqaf?

Il-maġġoranza tal-piż terġa' lura, tipikament fi żmien sena. It-titoli ta' rtirar huma konsistenti f'dan u huwa l-iktar ħaġa importanti li għandek tifhem qabel tibda.

Ikkawża telf ta' muskoli?

Telf rapidu tal-piż minn kwalunkwe kawża jinkludi tessut leani. L-intake ta' proteina u t-taħriġ ta' reżistenza huma l-mitigazzjonijiet li għandhom evidenza warajhom.

Huwa verżjoni komposta l-istess ħaġa?

Le. Preparazzjonijiet komposti mhumiex il-prodotti li ġew ittestjati, l-iżbalji fid-dożi huma dokumentati, u xi wħud jużaw forom ta' sħana li qatt ma ġew studjati f'nies.

Referenzi

Kull ċitazzjoni hawn taħt tgħaqqad mal-record oriġinali peer-reviewed fuq PubMed jew permezz ta' DOI. Xejn hawnhekk m'għandux ikun sostitut għal parir mediku.

Perioperative management of patients taking glucagon-like peptide 1 receptor agonists: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement Oprea AD, Ostapenko LJ, Sweitzer B, et al. · British journal of anaesthesia · 2025 · Systematic review DOI PubMed 40379536 Full text
Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials Karagiannis T, Malandris K, Avgerinos I, et al. · Diabetologia · 2024 · Meta-analysis DOI PubMed 38613667 Full text
Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Moiz A, Levett JY, Filion KB, et al. · The American journal of cardiology · 2024 · Meta-analysis DOI PubMed 38679221
EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) Journal of hepatology · 2024 · Clinical guideline DOI PubMed 38851997
Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis Yao H, Zhang A, Li D, et al. · BMJ (Clinical research ed.) · 2024 · Meta-analysis DOI PubMed 38286487 Full text
Quantified Metrics of Gastric Emptying Delay by Glucagon-Like Peptide-1 Agonists: A Systematic Review and Meta-Analysis With Insights for Periprocedural Management Hiramoto B, McCarty TR, Lodhia NA, et al. · The American journal of gastroenterology · 2024 · Meta-analysis DOI PubMed 38634551 Full text
Weight loss efficiency and safety of tirzepatide: A Systematic review Lin F, Yu B, Ling B, et al. · PloS one · 2023 · Meta-analysis DOI PubMed 37141329 Full text
Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis Tan HC, Dampil OA, Marquez MM · Journal of the ASEAN Federation of Endocrine Societies · 2022 · Meta-analysis DOI PubMed 36578889 Full text
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials Kristensen SL, Rørth R, Jhund PS, et al. · The lancet. Diabetes & endocrinology · 2019 · Meta-analysis DOI PubMed 31422062
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity Packer M, Zile MR, Kramer CM, et al. · The New England journal of medicine · 2025 · Randomised controlled trial DOI PubMed 39555826
Tirzepatide for Obesity Treatment and Diabetes Prevention Jastreboff AM, le Roux CW, Stefanski A, et al. · The New England journal of medicine · 2025 · Randomised controlled trial DOI PubMed 39536238
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes Rosenstock J, Hsia S, Nevarez Ruiz L, et al. · The New England journal of medicine · 2025 · Randomised controlled trial DOI PubMed 40544435
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment Wharton S, Aronne LJ, Stefanski A, et al. · The New England journal of medicine · 2025 · Randomised controlled trial DOI PubMed 40960239
Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis Bliddal H, Bays H, Czernichow S, et al. · The New England journal of medicine · 2024 · Randomised controlled trial DOI PubMed 39476339